These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34790672)

  • 1. Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis.
    Li N; Lv D; Zhu X; Wei P; Gui Y; Liu S; Zhou E; Zheng M; Zhou D; Zhang L
    Front Med (Lausanne); 2021; 8():728089. PubMed ID: 34790672
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis.
    Li N; Zhou G; Zheng Y; Lv D; Zhu X; Wei P; Zheng M; Liu S; Zhou E; Sun W; Zhang L
    PLoS One; 2022; 17(1):e0261986. PubMed ID: 35020750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Cao H; Rao X; Jia J; Yan T; Li D
    Acta Diabetol; 2023 Mar; 60(3):325-335. PubMed ID: 36316605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
    Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis.
    Yu B; Dong C; Hu Z; Liu B
    Medicine (Baltimore); 2021 Feb; 100(8):e24655. PubMed ID: 33663074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study.
    Yi TW; Atiquzzaman M; Zheng Y; Smyth B; Jardine M; Levin A
    Can J Kidney Health Dis; 2022; 9():20543581221145068. PubMed ID: 36578697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis.
    Liu T; Li R; Wang X; Gao X; Zhang X
    Med Clin (Barc); 2022 Jul; 159(2):65-72. PubMed ID: 34872768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
    Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
    Seidu S; Kunutsor SK; Cos X; Gillani S; Khunti K;
    Prim Care Diabetes; 2018 Jun; 12(3):265-283. PubMed ID: 29482993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
    Nagasu H; Yano Y; Kanegae H; Heerspink HJL; Nangaku M; Hirakawa Y; Sugawara Y; Nakagawa N; Tani Y; Wada J; Sugiyama H; Tsuruya K; Nakano T; Maruyama S; Wada T; Yamagata K; Narita I; Tamura K; Yanagita M; Terada Y; Shigematsu T; Sofue T; Ito T; Okada H; Nakashima N; Kataoka H; Ohe K; Okada M; Itano S; Nishiyama A; Kanda E; Ueki K; Kashihara N
    Diabetes Care; 2021 Nov; 44(11):2542-2551. PubMed ID: 34593566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria.
    Nakamura A; Miyoshi H; Kameda H; Yamashita K; Kurihara Y
    Diabetol Metab Syndr; 2020; 12():4. PubMed ID: 31938043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials.
    Chun KJ; Jung HH
    Kidney Med; 2021; 3(5):732-744.e1. PubMed ID: 34746739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia.
    Fernandez-Fernandez B; Sarafidis P; Kanbay M; Navarro-González JF; Soler MJ; Górriz JL; Ortiz A
    Clin Kidney J; 2020 Oct; 13(5):728-733. PubMed ID: 33123352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
    Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.